Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 22.81 percent decrease over losses of $(0.57) per share from the same period last year.